Revenue: As of FY2025 Q1, the actual value is USD 4.154 M.

EPS: As of FY2025 Q1, the actual value is USD -0.17.

Segment Revenue

• Total revenue for the first quarter of 2025 was $4.2 million, compared to $3.8 million for the same period in 2024. The increase was primarily due to a $1.0 million Phase 1 milestone payment and higher license fees, partially offset by lower service revenue.

Operational Metrics

• Research and development expenses decreased to $12.6 million from $14.6 million in the first quarter of 2024, mainly due to lower share-based compensation and external expenses.
• General and administrative expenses were $7.9 million, down from $8.3 million in the same period in 2024, primarily due to reduced legal fees and share-based compensation.
• Net loss for the first quarter of 2025 was $18.2 million, or $0.17 per share, compared to a net loss of $19.0 million, or $0.19 per share, for the same period in 2024.

Cash Flow

• As of March 31, 2025, OmniAb had cash, cash equivalents, and short-term investments totaling $43.6 million.

Unique Metrics

• OmniAb entered into three new platform license agreements during the first quarter of 2025, including partnerships with the Wyss Institute at Harvard University, Takis Biotech S.r.l., and Orion Corporation.

Outlook / Guidance

• OmniAb affirms its 2025 revenue guidance to be between $20 million and $25 million and revises operating expense guidance to be between $85 million and $90 million, down from the previous range of $90 million to $95 million.
• The company expects 2025 cash use to be lower than in 2024, which was $38.9 million, excluding the 2024 ATM issuance.
• The 2025 full-year effective tax rate is expected to be approximately 0%.